However, activation of myeloid cells is a key process in the pathology of many acute and chronic diseases so limiting this could have numerous advantages, but the most likely new use of a BTK inhibitor will in the treatment of acute inflammatory conditions, for example, sepsis, abdominal aortic aneurysm (AAA) or myocardial infraction. This evidence concerns the gene BTK and triple-A syndrome.